Hepatotoxicity of a Cannabidiol-Rich Cannabis Extract in the Mouse Model Laura E. Ewing, Charles M. Skinner, Charles M. Quick, Stefanie Kennon-McGill, Mitchell R. McGill, Larry A. Walker, Mahmoud A. ElSohly, Bill J. Gurley and Igor Koturbash Molecules, 2019, 24, 1694 doi : 10.3390/molecules24091694 Abstract : The goal of this study was to investigate Cannabidiol (CBD) hepatotoxicity in 8-week-old male B6C3F1 mice. Animals were gavaged with either 0, 246, 738, or 2460 mg/kg of CBD (acute toxicity, 24 h) or with daily doses of 0, 61.5, 184.5, or 615 mg/kg for 10 days (sub-acute toxicity). These doses were the allometrically scaled mouse equivalent doses (MED) [...]
Lire la suiteThe World Ayahuasca Diaspora. Reinventions and controversies Forword. Ayahuasca in the twenty-first century : having it both ways Glenn H. Shepard Jr. Museu Paraense Emílio Goeldi Edited by Beatriz Caiuby Labate, Clancy Cavnar, and Alex K. Gearin janvier 2017 The genie is out of the bottle, tweeting about the next shamanic bodywork leadership seminar, and the bottle; well, check and see if it isn’t in the back of your fridge by the vegan TV dinner. Who would have ever imagined that ayahuasca, the enigmatic jungle potion William S. Burroughs once referred to as “the secret” (Burroughs & Ginsberg, 2006 [1963]) and whose very botanical identity was a matter [...]
Lire la suiteCannabis à usage médical : la France saura-t-elle combler son retard ? Bertrand Lebeau Leibovici Médecin addictologue Membre fondateur du GRECC Juin 2019 Agnès Buzin réussira-t-elle là où Bernard Kouchner puis Marisole Touraine ont échoué ? En queue de peloton européen sur la question de l’accès au cannabis à usage thérapeutique, la France, reconnait l’actuelle ministre de la Santé, a pris du « retard ». Pour le rattraper, elle a demandé à l’Agence Nationale de Sécurité du Médicament (ANSM) de créer un Comité Scientifique Spécialisé Temporaire (CSST) présidé par le professeur Nicolas Authier, qui dirige aussi la Commission des Stupéfiants et Psychotropes, dans le cadre de l’ANSM. L’enfant chéri de l’Agence a [...]
Lire la suiteInternational Congress on Clinical Trials in Cannabis (CT-Cann2019), 24-25 October 2019, London, UK.
DEAR COLLEAGUES It is our pleasure to warmly invite you to participate in the upcoming International Congress on Clinical Trials in Cannabis (CT-Cann2019), which will take place on 24-25 October 2019 in London, UK. The endocannabinoid system is involved in numerous physiological and behavioral processes and, as such, has potential therapeutic implications relevant to many human diseases. Accordingly, in recent years there has been intense interest in the study and application of cannabinoid therapy in almost all areas of clinical medicine. However, while cannabinoids undoubtedly present us with many promising prospects and opportunities, translational and clinical cannabinoid research is, for the most part, [...]
Lire la suiteThe Cannabis Conundrum : Thinking Outside the THC Box Sarah L. Hagerty, Sophie L. York Williams, Vijay A. Mittal, and Kent E. Hutchison The Journal of Clinical Pharmacology, 2015, 55, 8, 839–841 DOI: 10.1002/jcph.511 Keywords : cannabis, cannabinoids, D9-tetrahydrocannabinol (THC), cannabidiol (CBD), psychosis Despite nationwide movements to legalize and regulate cannabis, our understanding of its effects on human health is tenuous at best. Developing a solid evidence base regarding the health effects of cannabis is imperative given the momentum for legalization and the demand for sound regulatory practices. This present commentary will identify limitations with respect to previous research on cannabis, discuss the genesis and implications [...]
Lire la suiteUsages d’alcool, de tabac et de cannabis chez les adolescents du secondaire en 2018 Stanislas Spilka, Emmanuelle Godeau (EHESP), Olivier Le Nézet, Virginie Ehlinger (Inserm UMR 1027), Eric Janssen, Alex Brissot, Antoine Philippon, Sandra Chyderiotis Tendances, juin 2018 Observatoire français des drogues et des toxicomanies Observer les premiers usages de substances psychoactives chez les adolescents selon le niveau scolaire [1, 2] permet d’analyser le calendrier de diffusion des consommations pour la mise en oeuvre d’actions de prévention et de politiques de santé publique : quand et où intervenir auprès des élèves, quelles sont les classes « pivots » au cours desquelles les expérimentations s’amorcent ou [...]
Lire la suiteTherapeutic Prospects of Cannabidiol for Alcohol Use Disorder and Alcohol-Related Damages on the Liver and the Brain Julia De Ternay, Mickaël Naassila Mikail Nourredine, Alexandre Louvet, François Bailly, Guillaume Sescousse, Pierre Maurage, Olivier Cottencin, Patrizia Maria Carrieri and Benjamin Rolland Frontiers in Pharmacology, 2019, Volume 10, Article 627 doi : 10.3389/fphar.2019.00627 Abstract Background : Cannabidiol (CBD) is a natural component of cannabis that possesses a widespread and complex immunomodulatory, antioxidant, anxiolytic, and antiepileptic properties. Much experimental data suggest that CBD could be used for various purposes in alcohol use disorder (AUD) and alcohol-related damage on the brain and the liver. Aim : To provide a rationale for [...]
Lire la suiteSerotonergic psychedelics and personality: a systematic review of contemporary research José Carlos Bouso, Rafael G. dos Santos, Miguel Ángel Alcázar-Córcoles, Jaime E. C. Hallak Neuroscience and Biobehavioral Reviews, 2018 PII: S0149-7634(17)30301-9 DOI: https://doi.org/10.1016/j.neubiorev.2018.02.004 Highlights Serotonergic psychedelics act as agonists at cortical 5-HT2A receptors 5-HT2A receptors are expressed in fronto-temporo-parieto-occipital areas Some personality traits seem to be related to 5-HT2A receptor expression Acute and long-term use of psychedelics is associated with personality changes Personality changes induced by psychedelics may have therapeutic effects Abstract Serotonergic psychedelics act as agonists at cortical 5-HT2A receptors and seem to induce personality changes. We conducted a systematic review of studies assessing the effects [...]
Lire la suitePsychological variables implied in the therapeutic effect of ayahuasca : a contextual approach. Alba Franquesa, Alberto Sainz-Cort, Sam Gandy, Joaquim Soler, Miguel Ángel Alcázar-Córcoles, José Carlos Bouso Psychiatry Research, 2017 PII: S0165-1781(17)31377-X DOI: 10.1016/j.psychres.2018.04.012 Abstract Ayahuasca is a psychedelic decoction originating from Amazonia. The ayahuasca-induced introspective experience has been shown to have potential benefits in the treatment of several pathologies, to protect mental health and to improve neuropsychological functions and creativity, and boost mindfulness. The underlying psychological processes related to the use of ayahuasca in a psychotherapeutic context are not yet well described in the scientific literature, but there is some evidence to suggest that psychological [...]
Lire la suiteAyahuasca : Uses, Phytochemical and Biological Activities, Edgar Antonio Estrella‑Parra et al., 2019
Ayahuasca : Uses, Phytochemical and Biological Activities Edgar Antonio Estrella‑Parra, · Julio Cesar Almanza‑Pérez, · Francisco Javier Alarcón‑Aguilar Natural Products and Bioprospecting, 2019 https://doi.org/10.1007/s13659-019-0210-5 Abstract Ayahuasca (caapi, yajé), is a psychoactive brew from the Amazon Basin region of South America traditionally considered a “master plant.” It is prepared as a decoction from Banisteriopsis caapi and Psychotria viridis, which it is thought that it stimulates creative thinking and visual creativity. Native healers of the Orinoco and Amazon basins have used traditionally ayahuasca as a healing tool for multiple purposes, particularly to treat psychological disorders in the patients, with some beneficial effects experimentally and clinically validated. Recently, [...]
Lire la suite